Dyne Therapeutics, Inc. (DYN)
$15.96-4.09%Close
SELLRECOVERY · day 3
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.6B
- Beta
- 1.12
- P/E (TTM)
- -4.62
- Short % float
- 19.28%
- Days to cover
- 9.0
- SI change
- +11.1%
- 1W
- +3.37%
- 1M
- -12.36%
- vs SPY 1W
- +2.95%
- vs SPY 1M
- -14.42%
Industry peers
FMP comparable companies · ranked by market cap
- IONSSELLIonis Pharmaceuticals, Inc.$7.3BRECOVERYQ 8$43.67-3.56%
- PTCTSELLPTC Therapeutics, Inc.$5.3BRECOVERYQ 18$62.92-2.75%
- SRPTSELLSarepta Therapeutics, Inc.$1.8BRECOVERYQ 13$17.44-2.30%
- STOKSELLStoke Therapeutics, Inc.$1.6BCRISISQ 10$24.15-2.38%
- SLDBSELLSolid Biosciences Inc.$661MCRISISQ -13$6.71-2.33%
- WVESELLWave Life Sciences Ltd.$646MCRISISQ 7$3.28-5.20%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on DYN?
- LOPJLB’s latest quantitative signal on Dyne Therapeutics, Inc. (DYN) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is DYN in?
- Dyne Therapeutics, Inc. (DYN) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Dyne Therapeutics, Inc. (DYN) do?
- Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystroph…